default author photo

Ana Vivancos

Vall d’Hebron Institute of Oncology (VHIO)

SCHOLARLY PAPERS

2

DOWNLOADS

86

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

A Phase Ii, Open-Label, Randomized Trial of Durvalumab with Olaparib or Cediranib in Patients with Mismatch Repair–Proficient Colorectal or Pancreatic Cancer

Number of pages: 54 Posted: 14 Mar 2024
Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology (VHIO), Ontario Institute for Cancer Research, Ontario Institute for Cancer Research, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre, University Health Network - Tumor Immunotherapy Program, University of Toronto - Princess Margaret Cancer Centre, University of Toronto - Princess Margaret Cancer Centre and University of Toronto - Princess Margaret Cancer Centre
Downloads 43 (1,157,785)

Abstract:

Loading...

Immunotherapy, biomarkers, colorectal, pancreatic, cancer, cold tumors

2.

A Pan-Cancer Clinical Platform to Predict Immunotherapy Outcomes and Prioritize Immuno-Oncology Combinations in Early-Phase Trials

Number of pages: 34 Posted: 17 Feb 2023
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), University of Montreal - Faculté de Pharmacie, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Université de Montréal - Faculty of Pharmacy, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, University Health Network - Princess Margaret Bioinformatics and Computational Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 43 (1,145,425)

Abstract:

Loading...